The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study

Background: Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to assess arterial stiffness. We aim to compare the effect of empagliflozin, liraglutide and their sequential combination on arterial stiffness indices in patients with type 2 diabetes (T2D).Methods: This was a randomized single blind study evaluating the effect of empagliflozin vs liraglutide in adult patients with T2D. Patients were randomized to liraglutide titrated gradually to 1.8 mg or empagliflozin 25 mg in 1:1 ratio. Three months later empagliflozin was added to the liraglutide group, and liraglutide was added to the empagliflozin group. Patients were assessed with non-invasive tests for arterial stiffness (i.e., carotid-femoral PWV and AIx of aortic pressure) at baseline, 3-month and 9-month visits (final visit was extended for 3 months from the initial design due to Covid 19 pandemic). The primary outcome was the between-group dif-ference of PWV change (APWV) and AAIx at 3 months. Secondary outcomes included the between-group dif-ference of APWV and AAIx at 9 months, as well as the APWV and AAIx between baseline and 9-month visit when total study population was assessed.Results: A total of 62 patients with T2D (30 started liraglutide; 32 empagliflozin, mean age 63 years, 25 % with established cardiovascular disease) participated in the study. We failed to show any significant between-group differences of APWV and AACYRILLIC CAPITAL LETTER BYELORUSSIAN-UKRAINIAN Ix at 3 and 9 months, as well as between-group difference of APWV and AAIx for the total study population between baseline and 9-month visit. In contrast, systemic vascular resistance and lipoprotein(a) levels improved, showing better results with liraglutide than empagliflozin. Favorable effects were also observed on body weight, body mass index, body and visceral fat, blood pressure, HbA1c, and uric acid levels.Conclusion: No evidence of a favorable change in arterial stiffness indices was seen with empagliflozin or lir-aglutide or their combination in this study. Well-designed powerful studies are needed to address any potential effects on arterial stiffness in selected populations.

Automated summary

This study compared the effects of empagliflozin, liraglutide, and their sequential combination on arterial stiffness indices in patients with type 2 diabetes. The results showed that neither empagliflozin nor liraglutide, nor their combination, had a significant favorable impact on arterial stiffness indices.